Physostigmine
SENSORY ORGANS
Also known as: (-)-Physostigmine, cogmine, eserine, eserine hemisulfate, eserine hemisulfate salt, esromiotin, physostigmine salicylate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Physostigmine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1875. DrugCentral lists 14 molecular targets, including ACHE, Ache and Ache. Recorded indications include Anticholinergic Toxicity and Open-angle glaucoma.
- Molecular targets: ACHE, Ache, Ache and Bche (14 listed in DrugCentral).
- Indications: Anticholinergic Toxicity and Open-angle glaucoma.
- ATC code: S01EB05 (Parasympathomimetics).
- Molecular formula: C15H21N3O2; molecular weight 275.35 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Anticholinergic Toxicity
- Open-angle glaucoma
Off-label uses (3)
- Angle-closure glaucoma
- Hereditary Ataxias
- Secondary glaucoma
Contraindications (15)
- Anterior uveitis
- Asthma
- Bradycardia
- Diabetes mellitus
- Disorder of cardiovascular system
- Epilepsy
- Gangrene
- Gastrointestinal obstruction
- Iritis
- Keratitis
- Neuromuscular block, function
- Parkinsonism
- Pupillary Block Glaucoma
- Retinal detachment
- Urinary tract obstruction
Mechanism & targets
Molecular targets (14)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Acetylcholinesterase | ACHE | inhibitor | IC50 9.37 |
| Acetylcholinesterase | Ache | unknown | IC50 9.17 |
| Acetylcholinesterase | Ache | unknown | IC50 9.17 |
| Butyrylcholinesterase; Protein Bche | Bche | unknown | IC50 8.12 |
| Acetylcholinesterase | ache | unknown | IC50 7.96 |
| Butyrylcholinesterase | BCHE | unknown | IC50 7.80 |
| Acetylcholinesterase | ACHE | unknown | IC50 7.70 |
| Acetylcholinesterase | ACHE | unknown | IC50 7.52 |
| Acetylcholinesterase | ache | unknown | Ki 7.47 |
| Cholinesterase | BCHE | unknown | Ki 7.39 |
| Cytochrome P450 2D6 | CYP2D6 | unknown | IC50 6.70 |
| Cholinesterase | Bche | unknown | IC50 6.55 |
| Cholinesterase | BCHE | unknown | Ki 5.30 |
| Muscarinic acetylcholine receptor M1 | Chrm1 | unknown | IC50 4.43 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1875-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
S01EB05 | SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Parasympathomimetics |
V03AB19 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Antidotes |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Anticholinergic syndrome | 121.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Physostigmine is on its molecule page.
| Molecular formula | C15H21N3O2 |
|---|---|
| Molecular weight | 275.35 g/mol |
| CAS number | 57-47-6 |
| InChIKey | PIJVFDBKTWXHHD-HIFRSBDPSA-N |
| PubChem CID | 5983 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Physostigmine used for?
DrugCentral lists the following indications for Physostigmine: Anticholinergic Toxicity and Open-angle glaucoma.
How does Physostigmine work?
Its molecular targets in DrugCentral include ACHE (inhibitor), Ache, Ache and Bche.
When was Physostigmine first approved?
Physostigmine was first approved by the YEAR INTRODUCED in 1875.
What is the chemical formula of Physostigmine?
Physostigmine has the molecular formula C15H21N3O2 and a molecular weight of 275.35 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2159 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2105891 — compound record and bioactivity
- PubChem CID 5983 — chemical identifiers
- DrugBank DB00981 — drug record
- FDA UNII 9U1VM840SP — substance identity
- UniProt P22303 (ACHE) — target protein
- UniProt P10635 (CYP2D6) — target protein
- UniProt P06276 (BCHE) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.